CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 424 enrolled
Drug / intervention
ReWalk 6.0device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02658656
NCT02658656N/ACompleted
CompareCT.gov

CSP #2003 - Exoskeleton Assisted-Walking in Persons With SCI: Impact on Quality of Life

VA Office of Research and Development·interventional·Posted Jan 20, 2016·Updated Nov 4, 2024

In Brief

A clinical study evaluating ReWalk 6.0 for Spinal Cord Injury. Completed, enrolled 424 participants across 15 sites.

Detailed Summary

Background Veterans with spinal cord injury (SCI) have many adverse secondary medical and quality of life (QOL) changes as a result of immobilization. Veterans with SCI who have completed rehabilitation after injury and are unable to ambulate receive a wheelchair as standard of care (SOC) for mobility. Powered exoskeletons are a technology that has recently become available as an alternate form of mobility by providing an external framework for support and computer controlled motorized hip and knee joints to assist with over ground ambulation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injury
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 20, 2016
Enrollment StartAug 1, 2016
Primary CompletionMar 31, 2021
Study CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 10.5 years ago

Interventions

ReWalk 6.0device

Exoskeletal Assisted Walking Device